Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Men who have sex with men

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    165 result(s) found for: Men who have sex with men. Displaying page 1 of 9.
    1  2  3  4  5  6  7  8  9  Next»
    EudraCT Number: 2018-003666-13 Sponsor Protocol Number: VAC89220HPX3002 Start Date*: 2019-10-15
    Sponsor Name:Janssen Vaccines & Prevention B.V.
    Full Title: A Multi-center, Randomized, Double-blind, Placebo-controlled Phase 3 Efficacy Study of a Heterologous Vaccine Regimen of Ad26.Mos4.HIV and Adjuvanted Clade C gp140 and Mosaic gp140 to Prevent HIV-1...
    Medical condition: Prevention of HIV-1 Infection
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004862 10068341 HIV-1 infection LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Restarted) PL (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-000215-24 Sponsor Protocol Number: GeSIDA10017 Start Date*: 2018-06-05
    Sponsor Name:Fundacion SEIMC-GESIDA
    Full Title: A single-arm, open-label and multicentre phase IV trial to evaluate the immunogenicity of the nonavalent vaccine against human papillomavirus in HIV-infected men who have sex with men. GESIDA 10017...
    Medical condition: AIDS
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2023-001025-23 Sponsor Protocol Number: GS-US-528-9023 Start Date*: 2025-02-14
    Sponsor Name:Gilead Sciences, Inc.
    Full Title: A Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly Long-Acting Lenacapavir for HIV Pre-Exposure Prophylaxis in Cisgender Men, Tr...
    Medical condition: Pre-Exposure Prophylaxis of HIV Infection
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021881 - Infections and infestations 10068341 HIV-1 infection LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: (No results available)
    EudraCT Number: 2015-004524-65 Sponsor Protocol Number: Inf.Q002 Start Date*: 2015-11-30
    Sponsor Name:Department of Infectious Diseases
    Full Title: Efficacy of nonavalent vaccine against human papilloma virus (HPV ) in HIV infected sexually active men who have sex with men (MSM)
    Medical condition: The purpose of the study is to investigate the efficacy of a new nonavalent HPV vaccine in sexually active HIV-infected MSM.
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004862 10063001 Human papilloma virus infection LLT
    18.1 100000004865 10071147 Human papilloma virus immunization LLT
    Population Age: Adults Gender: Male
    Trial protocol: DK (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2016-001399-31 Sponsor Protocol Number: GS-US-412-2055 Start Date*: 2016-12-13
    Sponsor Name:Gilead Sciences, Inc.
    Full Title: A Phase 3, Randomized, Double-blind Study to Evaluate the Safety and Efficacy of Emtricitabine and Tenofovir Alafenamide (F/TAF) Fixed-Dose Combination Once Daily for Pre-Exposure Prophylaxis in Me...
    Medical condition: Healthy volunteers (Pre-exposure prophylaxis (PrEP) of human immunodeficiency virus 1 (HIV-1))
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004865 10073527 HIV pre-exposure prophylaxis LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Ongoing) IE (Trial now transitioned) AT (Trial now transitioned) DK (Trial now transitioned) NL (Completed) ES (Ongoing) FR (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-001730-18 Sponsor Protocol Number: TreatAIN Start Date*: 2019-09-27
    Sponsor Name:Fundación Hospital Vall d'Hebron- Institut de Recerca
    Full Title: Phase III, random, one-site, pilot, open, parallell group trial for evaluating the eficacy and safety of electrocoagulation vs topic sinecatechins vs topic cidofovir in the High-grade anal intraepi...
    Medical condition: High-grade anal intraepithelial neoplasia
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-002758-22 Sponsor Protocol Number: V503-003 Start Date*: 2012-12-27
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
    Full Title: A Phase III Clinical Trial to Study the Tolerability and Immunogenicity of V503, a Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine, in 16- to 26-Year-Old Men and 16- to ...
    Medical condition: Prevention of external genital lesions, anal cancers and related precancers, and persistent infection caused by Human Papillomavirus (HPV) 6, 11, 16, 18, 31, 33, 45, 52 and 58.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10063001 Human papilloma virus infection LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) FI (Not Authorised) SE (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2004-002945-10 Sponsor Protocol Number: V501-020 Start Date*: 2005-02-18
    Sponsor Name:Suomen MSD OY
    Full Title: A Study to Evaluate the Efficacy of Quadrivalent HPV (Types 6, 11, 16, and 18) L1 Virus-Like Particle (VLP) in Reducing the Incidence of HPV 6-, 11-, 16-, and 18-Related Anogenital Warts, and the I...
    Medical condition: Prevention of Human Papillomavirus Infections
    Disease: Version SOC Term Classification Code Term Level
    7.0 10063001 LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male
    Trial protocol: FI (Completed) SE (Completed) DE (Completed) ES (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2015-002931-16 Sponsor Protocol Number: V501-122 Start Date*: 2018-02-09
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase III Placebo-controlled Clinical Trial to Study the Tolerability, Immunogenicity and Efficacy of V501 in 16- to 26-year-old Japanese men
    Medical condition: vaccination against HPV infection/related disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004865 10071147 Human papilloma virus immunization LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2012-001258-25 Sponsor Protocol Number: MK8962-031-00 Start Date*: 2012-11-29
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A phase III, multi-center, open label, uncontrolled trial to investigate the efficacy and safety of MK-8962 (corifollitropin alfa) in combination with human Chorionic Gonadotropin (hCG) in inducing...
    Medical condition: Hypogonadotropic hypogonadism (HH) in males may result from either absent or inadequate gonadotropin-releasing hormone (GnRH) secretion by the hypothalamus or failure of pituitary gonadotropin secr...
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004860 10021012 Hypogonadotrophic hypogonadism LLT
    Population Age: Adults Gender: Male
    Trial protocol: DE (Completed) ES (Completed) IT (Completed) GB (Completed) PL (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2012-002373-56 Sponsor Protocol Number: Start Date*: 2012-10-02
    Sponsor Name:Medical Research Council
    Full Title: PRe-exposure Option for reducing HIV in the UK: an open-label randomisation to immediate or Deferred daily Truvada for HIV negative gay men
    Medical condition: HIV infection
    Disease: Version SOC Term Classification Code Term Level
    14.1 10042613 - Surgical and medical procedures 10054925 Prophylaxis against HIV infection PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2021-000248-23 Sponsor Protocol Number: C3441052 Start Date*: 2021-10-22
    Sponsor Name:Pfizer Inc.
    Full Title: TALAPRO-3: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER
    Medical condition: Metastatic Castration-sensitive Prostate Cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: CZ (Trial now transitioned) DE (Trial now transitioned) FR (Trial now transitioned) NO (Trial now transitioned) SK (Trial now transitioned) FI (Trial now transitioned) BE (Trial now transitioned) NL (Trial now transitioned) ES (Ongoing) BG (Trial now transitioned) HU (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2014-002569-32 Sponsor Protocol Number: izoz/0025 Start Date*: 2015-06-12
    Sponsor Name:Academic Medical Center
    Full Title: Biomedical interventions for HIV prevention in MSM in Amsterdam: a demonstration project
    Medical condition: prevention of HIV infection
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-001558-26 Sponsor Protocol Number: ADG103440 Start Date*: 2005-10-11
    Sponsor Name:GlaxoSmithKline, S.A.
    Full Title: A RANDOMISED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO-CONTROLLED, MULTICENTRE STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND EFFICACY OF ORAL GW677954 CAPSULES 2.5mg, 5mg, 10mg AND 20mg A DAY FOR WEE...
    Medical condition: Dyslipidaemia and overweight
    Disease: Version SOC Term Classification Code Term Level
    7.1 10052066 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) SK (Completed) LV (Completed)
    Trial results: View results
    EudraCT Number: 2016-002036-32 Sponsor Protocol Number: C3441006(MDV3800-06) Start Date*: 2016-12-05
    Sponsor Name:Pfizer Inc.
    Full Title: TALAPRO 1: A PHASE 2, OPEN LABEL, RESPONSE RATE STUDY OF TALAZOPARIB IN MEN WITH DNA REPAIR DEFECTS AND METASTATIC CASTRATION RESISTANT PROSTATE CANCER WHO PREVIOUSLY RECEIVED TAXANE BASED CHEMOTHE...
    Medical condition: Men With DNA Repair Defects and Metastatic Castration-Resistant Prostate Cancer Who Previously Received Taxane-Based Chemotherapy and Progressed on at Least 1 Novel Hormonal Agent (Enzalutamide and...
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10076506 Castration-resistant prostate cancer LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DE (Completed) NL (Completed) ES (Ongoing) FR (Completed) BE (Completed) GB (Completed) AT (Completed) DK (Prematurely Ended) HU (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2020-003309-79 Sponsor Protocol Number: MK-8591-024 Start Date*: 2021-04-30
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase 3, Randomized, Active-Controlled, Double-Blind Clinical Study to Evaluate the Efficacy and Safety of Oral Islatravir Once-Monthly as Preexposure Prophylaxis in Cisgender Men and Transgender...
    Medical condition: HIV Preexposure prophylaxis
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004862 10068341 HIV-1 infection LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2020-002118-42 Sponsor Protocol Number: ALT-301-202 Start Date*: 2020-12-17
    Sponsor Name:Altimmune, Inc.
    Full Title: Phase 2, Double-blind, Randomized, Placebo-controlled Study of HepTcell (Adjuvanted FP-02.2) as an Immunotherapeutic Vaccine in Treatment naïve Patients with Inactive Chronic Hepatitis B (CHB)
    Medical condition: Inactive Chronic Hepatitis B (CHB)
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021881 - Infections and infestations 10008910 Chronic hepatitis B PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (GB - no longer in EU/EEA) IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2007-000427-17 Sponsor Protocol Number: CY503C1 Start Date*: 2007-10-26
    Sponsor Name:CYTAVIS BioPharma GmbH
    Full Title: A phase II multicenter study to test progression- free and overall survival of CY-503 in the treatment of patients with unresectable stage IV metastatic melanoma after antineoplastic treatment failure
    Medical condition: unresectable progressive metastatic melanoma stage IV after antineoplastic treatmet failure
    Disease: Version SOC Term Classification Code Term Level
    9.1 10027152 Melanoma of skin (malignant) LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-000982-51 Sponsor Protocol Number: P05336 Start Date*: 2009-07-01
    Sponsor Name:Schering-Plough Research Institute, a Division of Schering Corporation
    Full Title: Infliximab as First Line Therapy in Patients with Early Active Axial Spondyloarthritis Trial
    Medical condition: Moderate-to-severe active axial spondyloarthritis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10058338 Spondylarthritis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Completed) AT (Completed) BE (Completed) DE (Completed) HU (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2021-000016-28 Sponsor Protocol Number: 212483 Start Date*: 2021-08-24
    Sponsor Name:ViiV Healthcare UK Limited
    Full Title: A Phase IIb, randomized, double-blind, parallel-group study to assess the efficacy, safety, tolerability, and resistance profile of GSK3640254 in combination with dolutegravir compared to dolutegra...
    Medical condition: Human Immunodeficiency Virus Type-1 (HIV-1)
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004862 10068341 HIV-1 infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) DE (Completed) PT (Prematurely Ended) ES (Ongoing) IT (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun Jun 01 13:02:06 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA